An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease

The readout sets the bar for Bristol Myers Squibb and Johnson & Johnson in a blockbuster indication ahead of data on their rival factor XIa inhibitor.
Nick Paul Taylor Feb 5, 2026 12:15pm
IPO initial public offering Wall Street

Eikon upsized $381M listing marks largest biotech IPO since 2024

Feb 5, 2026 4:23am
Inside Henlius global growth strategy

Inside Henlius’ global growth strategy

Feb 2, 2026 8:00am
Hundred dollar bills flowing out of faucet

Angitia raises $130M to advance bone-building bispecifics

Feb 5, 2026 10:17am
x

Fierce Biotech Layoff Tracker 2026: ARPA-H, GSK & more

Feb 5, 2026 2:55pm
Astellas
Favicon Fierce Pharma

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am
More News
Fierce Pharma

Veradermics locks in $256M IPO, shares spike

Feb 5, 2026 10:01am

Fierce Biotech Fundraising Tracker '26: Angitia & more

Feb 5, 2026 9:30am

Flagship-founded antibody biotech Generate is latest to mull IPO

Feb 5, 2026 9:20am

Quell halts transplant trial to focus on 'chill not kill' Treg

Feb 5, 2026 6:00am